IL193196A - Vaccine comprising a yeast vehicle and an influenza virus fusion protein - Google Patents

Vaccine comprising a yeast vehicle and an influenza virus fusion protein

Info

Publication number
IL193196A
IL193196A IL193196A IL19319608A IL193196A IL 193196 A IL193196 A IL 193196A IL 193196 A IL193196 A IL 193196A IL 19319608 A IL19319608 A IL 19319608A IL 193196 A IL193196 A IL 193196A
Authority
IL
Israel
Prior art keywords
vaccine
protein
yeast
influenza
anyone
Prior art date
Application number
IL193196A
Other languages
English (en)
Hebrew (he)
Other versions
IL193196A0 (en
Original Assignee
Globeimmune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Globeimmune Inc filed Critical Globeimmune Inc
Publication of IL193196A0 publication Critical patent/IL193196A0/en
Publication of IL193196A publication Critical patent/IL193196A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16311—Influenzavirus C, i.e. influenza C virus
    • C12N2760/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
IL193196A 2006-02-02 2008-07-31 Vaccine comprising a yeast vehicle and an influenza virus fusion protein IL193196A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US76502506P 2006-02-02 2006-02-02
PCT/US2007/061572 WO2007092792A2 (en) 2006-02-02 2007-02-02 Yeast-based vaccine for inducing an immune response

Publications (2)

Publication Number Publication Date
IL193196A0 IL193196A0 (en) 2011-08-01
IL193196A true IL193196A (en) 2015-01-29

Family

ID=38345897

Family Applications (2)

Application Number Title Priority Date Filing Date
IL193196A IL193196A (en) 2006-02-02 2008-07-31 Vaccine comprising a yeast vehicle and an influenza virus fusion protein
IL232518A IL232518A0 (en) 2006-02-02 2014-05-08 A yeast-based vaccine to stimulate an immune response

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL232518A IL232518A0 (en) 2006-02-02 2014-05-08 A yeast-based vaccine to stimulate an immune response

Country Status (14)

Country Link
US (2) US7736642B2 (esLanguage)
EP (2) EP1988919A4 (esLanguage)
JP (3) JP5198290B2 (esLanguage)
KR (2) KR101492524B1 (esLanguage)
CN (2) CN101405026B (esLanguage)
AU (1) AU2007212076B2 (esLanguage)
BR (1) BRPI0706913A2 (esLanguage)
CA (1) CA2638815A1 (esLanguage)
IL (2) IL193196A (esLanguage)
IN (1) IN2014DN08830A (esLanguage)
MX (1) MX2008009929A (esLanguage)
SG (2) SG169375A1 (esLanguage)
TW (2) TW200806316A (esLanguage)
WO (1) WO2007092792A2 (esLanguage)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US8343502B2 (en) * 2002-12-16 2013-01-01 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
CA2898163C (en) * 2002-12-16 2016-10-11 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
KR20080043775A (ko) * 2005-07-11 2008-05-19 글로브이뮨 표적 치료용 회피 돌연변이체에 대한 면역 반응의 유발방법 및 조성물
US20070172503A1 (en) * 2005-12-13 2007-07-26 Mycologics,Inc. Compositions and Methods to Elicit Immune Responses Against Pathogenic Organisms Using Yeast Based Vaccines
IN2014DN08830A (esLanguage) * 2006-02-02 2015-07-10 Globeimmune Inc
GB0613977D0 (en) 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
WO2007130330A2 (en) * 2006-05-01 2007-11-15 Technovax, Inc. Polyvalent influenza virus-like particle (vlp) compositions
WO2008054535A2 (en) * 2006-05-11 2008-05-08 Novavax, Inc. Novel influenza m2 vaccines
DK2023952T3 (en) * 2006-05-18 2015-10-19 Epimmune Inc Induction of immune responses to influenza virus using polypeptide and nucleic acid compositions
EP2121013B1 (en) * 2007-02-02 2014-10-15 Globeimmune, Inc. Methods for producing yeast-based vaccines
NZ580444A (en) * 2007-03-19 2012-02-24 Globeimmune Inc Compositions and methods for targeted ablation of mutational escape of targeted therapies for cancer
US20100285050A1 (en) 2007-10-05 2010-11-11 Isis Innovation Limited Compositions and Methods
GB0719526D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
US20110177122A1 (en) * 2008-09-26 2011-07-21 The United States Of America, As Represented By The Secretary, Dept. Of Health & Human Services Dna prime/activated vaccine boost immunization to influenza virus
MX2011010977A (es) 2009-04-17 2012-02-29 Us Health Composiciones inmunoterapeuticas combinadas contra cancer y metodos.
EP2432503A4 (en) * 2009-05-18 2013-01-23 Panacea Biotec Ltd BASED ON RECOMBINANTLY MODIFIED VACCINIA ANKARA VIRUS UNIVERSAL GRIP VACCINATE
EP2477647B1 (en) 2009-09-14 2016-01-13 The Regents of the University of Colorado Modulation of yeast-based immunotherapy products and responses
US20120015346A1 (en) * 2010-07-08 2012-01-19 New York Medical College Influenza virus detection and diagnosis
EP2624864B1 (en) * 2010-10-04 2017-12-06 Massachusetts Institute of Technology Hemagglutinin polypeptides, and reagents and methods relating thereto
CA2813685A1 (en) * 2010-10-15 2012-04-19 Josef Weigl Recombinant modified vaccinia virus ankara influenza vaccine
ES2696551T3 (es) * 2010-12-17 2019-01-16 Globeimmune Inc Composiciones y métodos para el tratamiento o la prevención de la infección por adenovirus-36 humano
JP6169494B2 (ja) * 2011-01-31 2017-07-26 ナノセラピューティクス・インコーポレイテッドＮａｎｏｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． インフルエンザａウイルスに対するヘテロサブタイプ免疫応答を誘導するための組換えウイルスベクターおよび方法
KR102026840B1 (ko) 2011-02-12 2019-09-30 글로브이뮨 만성적인 b형 간염에 대한 효모-기반의 치료제
SG193396A1 (en) 2011-03-17 2013-10-30 Globeimmune Inc Yeast-brachyury immunotherapeutic compositions
US20140377295A1 (en) * 2011-05-23 2014-12-25 The Wistar Institute Of Anatomy And Biology Influenza vaccines containing modified adenovirus vectors
BR112013032381B1 (pt) * 2011-06-14 2021-01-12 Globeimmune, Inc. composições à base de levedura e métodos para o tratamento ou prevenção de infecção pelo vírus da hepatite delta
BR112013032723A2 (pt) * 2011-06-20 2017-01-31 Univ Pittsburgh Commonwealth Sys Higher Education antígenos amplamente reativos computacionalmente otimizados para influenza h1n1
WO2013025972A1 (en) 2011-08-17 2013-02-21 Globeimmune, Inc. Yeast-muc1 immunotherapeutic compositions and uses thereof
ES2525205T3 (es) * 2011-11-09 2014-12-18 Werner Lubitz Vacuna para su uso en inmunoterapia tumoral
DE102011121069A1 (de) 2011-12-13 2013-06-13 Martin-Luther-Universität Halle-Wittenberg Vakzinierung mittels rekombinanter Hefe durch Erzeugung einer protektiven humoralen Immunantwort gegen definierte Antigene
KR102103319B1 (ko) 2012-06-26 2020-04-22 바이오디식스, 인크. 면역반응 발생 요법으로 치료하기 위해 암환자들의 선택, 및 선택해제를 위한 질량-스펙트럼법
US20140065173A1 (en) 2012-09-06 2014-03-06 Orbis Health Solutions Llc Tumor lysate loaded particles
JP5954079B2 (ja) 2012-09-25 2016-07-20 ソニー株式会社 培養観察装置及び培養観察方法
WO2014093357A1 (en) * 2012-12-10 2014-06-19 The University Of Queensland Cell-free biofragment compositions and related systems, devices, and methods
JP2016514672A (ja) * 2013-03-15 2016-05-23 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 抗原およびアジュバントとしてのインターロイキン−２３を有するワクチン
EP2976100B1 (en) 2013-03-19 2020-07-01 Globeimmune, Inc. Yeast-based immunotherapy for chordoma
TWI626948B (zh) * 2013-03-26 2018-06-21 環球免疫公司 治療或預防人類免疫缺乏病毒感染之組合物及方法
JP2014210747A (ja) * 2013-04-19 2014-11-13 アンジェスＭｇ株式会社 細胞性免疫誘導能が改善された経口ワクチン
WO2015031778A2 (en) 2013-08-30 2015-03-05 Globeimmune, Inc. Compositions and methods for the treatment or prevention of tuberculosis
KR20220062143A (ko) 2014-01-06 2022-05-13 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Pd1 및 pdl1 항체 및 백신 조합 및 면역요법을 위한 이들의 사용
CA2941633C (en) 2014-03-05 2021-01-12 Orbis Health Solutions Llc Vaccine delivery systems using yeast cell wall particles
US10799567B2 (en) 2014-04-11 2020-10-13 Globeimmune, Inc. Yeast-based immunotherapy and type I interferon sensitivity
CN105233302B (zh) * 2014-07-10 2018-10-19 中国人民解放军军事医学科学院生物工程研究所 一种流感血凝素糖蛋白多聚物纳米颗粒的制备方法
ES2795833T3 (es) 2015-01-09 2020-11-24 Etubics Corp Composiciones para la vacunación contra el virus del Ebola
WO2016168187A1 (en) * 2015-04-13 2016-10-20 The Regents Of The University Of Michigan Virus-like particles
JP6789283B2 (ja) 2015-08-03 2020-11-25 グローブイミューン，インコーポレイテッド 改変酵母−ブラキュリー免疫療法組成物
AU2016304853C1 (en) * 2015-08-11 2023-03-16 Orbis Health Solutions Llc Bacterial and viral vaccine strategy
GB2552441A (en) * 2015-10-22 2018-01-31 Royal Veterinary College Methods
EP3195878A1 (en) 2016-01-22 2017-07-26 Werner Lubitz Bacterial ghosts for the treatment of cancer
AU2017281126A1 (en) 2016-03-24 2018-10-04 Nant Holdings Ip, Llc Sequence arrangements and sequences for neoepitope presentation
EP3615675A4 (en) 2017-04-24 2021-03-03 Nantcell, Inc. TARGETED NEO-EPITOPIC VECTORS AND ASSOCIATED PROCESSES
EP3730620A4 (en) 2017-12-21 2022-01-05 Green Biomed, Inc. Cross-immunizing antigen vaccine and method for preparation thereof
DE102017012109A1 (de) 2017-12-27 2019-06-27 Martin-Luther-Universität Halle-Wittenberg Optimiertes Wirts-/Vektorsystem zur Erzeugung protektiver mono- und multivalenter subunit-Vakzine auf Basis der Hefe Kluyveromyces lactis
CN119818663A (zh) * 2018-05-15 2025-04-15 全球免疫公司 用于诱导细胞免疫应答的重组酵母裂解物
CN111315407B (zh) * 2018-09-11 2023-05-02 上海市公共卫生临床中心 一种广谱抗流感疫苗免疫原及其应用
US20210290708A1 (en) 2018-09-21 2021-09-23 Nantcell, Inc. Methods and compositions for modulating myeloid-derived suppressor cells
AU2020279381A1 (en) * 2019-05-21 2021-12-09 Esperovax Inc. Yeast-based oral vaccination
KR20220152226A (ko) * 2020-02-11 2022-11-15 사이토누스 테라퓨틱스, 인크. 신속한 백신 플랫폼
US20210284716A1 (en) 2020-03-11 2021-09-16 Immunitybio, Inc. ACE2-Fc Trap
US12285480B2 (en) 2020-03-11 2025-04-29 Nantcell, Inc. Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses
US11857620B2 (en) 2020-03-11 2024-01-02 Immunitybio, Inc. Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus
WO2021211691A1 (en) 2020-04-14 2021-10-21 Immunitybio, Inc. Yeast lysate covid-19 vaccine

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5830463A (en) * 1993-07-07 1998-11-03 University Technology Corporation Yeast-based delivery vehicles
US5413914A (en) 1993-07-07 1995-05-09 The Regents Of The University Of Colorado Yeast assay to identify inhibitors of dibasic amino acid processing endoproteases
WO1995018861A1 (en) 1994-01-11 1995-07-13 Vlaams Interuniversitair Instituut Voor Biotechnologie Influenza vaccine
US5691189A (en) * 1994-01-19 1997-11-25 Bristol-Myers Squibb Company Saccharomyces cerevisiae expressing M2 protein of influenza A virus
US6696251B1 (en) * 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
US20020044948A1 (en) * 2000-03-15 2002-04-18 Samir Khleif Methods and compositions for co-stimulation of immunological responses to peptide antigens
JP5008244B2 (ja) * 2000-06-23 2012-08-22 ワイス・ホールディングズ・コーポレイション 野性型およびキメラのインフルエンザウイルス様粒子（ｖｌｐ）のアセンブリー
AU2002225681A1 (en) * 2000-11-15 2002-05-27 Globe Immune, Inc. Yeast-dentritic cell vaccines and uses thereof
US20030008000A1 (en) * 2001-03-08 2003-01-09 Wong Jonathan P. DNA vaccine using liposome-encapsulated plasmid DNA encoding for hemagglutinin protein of influenza virus
US20030202982A1 (en) * 2001-08-15 2003-10-30 Birkett Ashley J. Influenza immunogen and vaccine
US7439042B2 (en) 2002-12-16 2008-10-21 Globeimmune, Inc. Yeast-based therapeutic for chronic hepatitis C infection
CA2898163C (en) * 2002-12-16 2016-10-11 Globeimmune, Inc. Yeast-based vaccines as immunotherapy
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
WO2005116270A2 (en) * 2004-05-18 2005-12-08 Vical Incorporated Influenza virus vaccine composition and method of use
ES2375995T3 (es) * 2004-09-17 2012-03-08 University Of Massachusetts Composiciones y sus usos para deficiencias de enzima lisosomal.
IN2014DN08830A (esLanguage) * 2006-02-02 2015-07-10 Globeimmune Inc

Also Published As

Publication number Publication date
KR20140029551A (ko) 2014-03-10
EP2468296A2 (en) 2012-06-27
EP1988919A4 (en) 2009-06-10
SG10201402236VA (en) 2014-08-28
TW200806316A (en) 2008-02-01
CN101405026B (zh) 2015-04-22
WO2007092792A2 (en) 2007-08-16
EP2468296A3 (en) 2013-12-04
IN2014DN08830A (esLanguage) 2015-07-10
CN104826102A (zh) 2015-08-12
JP5198290B2 (ja) 2013-05-15
KR20080089671A (ko) 2008-10-07
MX2008009929A (es) 2008-10-01
AU2007212076A1 (en) 2007-08-16
SG169375A1 (en) 2011-03-30
WO2007092792A3 (en) 2008-02-28
KR101492524B1 (ko) 2015-02-12
IL193196A0 (en) 2011-08-01
TW201412329A (zh) 2014-04-01
US20080003239A1 (en) 2008-01-03
JP2009528987A (ja) 2009-08-13
JP2013075899A (ja) 2013-04-25
CA2638815A1 (en) 2007-08-16
BRPI0706913A2 (pt) 2011-04-12
JP2015038147A (ja) 2015-02-26
EP1988919A2 (en) 2008-11-12
US20100196411A1 (en) 2010-08-05
AU2007212076B2 (en) 2012-10-18
CN101405026A (zh) 2009-04-08
US7736642B2 (en) 2010-06-15
IL232518A0 (en) 2014-06-30

Similar Documents

Publication Publication Date Title
IL193196A (en) Vaccine comprising a yeast vehicle and an influenza virus fusion protein
JP2009528987A5 (esLanguage)
Pillet et al. A plant-derived quadrivalent virus like particle influenza vaccine induces cross-reactive antibody and T cell response in healthy adults
Eliasson et al. M2e-tetramer-specific memory CD4 T cells are broadly protective against influenza infection
Ansaldi et al. Cross-protection by MF59™-adjuvanted influenza vaccine: Neutralizing and haemagglutination-inhibiting antibody activity against A (H3N2) drifted influenza viruses
JP6826027B2 (ja) インフルエンザ抗原送達用のベクターおよび構築体
Cox Correlates of protection to influenza virus, where do we go from here?
Babapoor et al. A novel vaccine using nanoparticle platform to present immunogenic M2e against avian influenza infection
Zhang et al. Advancements in the development of subunit influenza vaccines
Lo et al. Comparison of vaccines for induction of heterosubtypic immunity to influenza A virus: cold-adapted vaccine versus DNA prime-adenovirus boost strategies
Zheng et al. Development of universal influenza vaccines based on influenza virus M and NP genes
CA2632483C (en) Improved influenza vaccine
EP3199545A3 (en) Computationally optimized broadly reactive antigens for h1n1 influenza
Gao et al. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge
RU2015138530A (ru) Комбинированная вакцина против респираторно-синцитиального вируса и вируса гриппа
Lee et al. AS04-adjuvanted virus-like particles containing multiple M2 extracellular domains of influenza virus confer improved protection
Du et al. Flu universal vaccines: new tricks on an old virus
HK1203524A1 (en) Computationally optimized broadly reactive antigens for h3n2, h2n2, and b influenza viruses
CA2434000A1 (en) Adjuvant viral particle
Saad-Roy et al. Dynamic perspectives on the search for a universal influenza vaccine
WO2016100922A1 (en) Synergistic co-administration of computationally optimized broadly reactive antigens for h1n1 influenza
Wohlbold et al. An H10N8 influenza virus vaccine strain and mouse challenge model based on the human isolate A/Jiangxi-Donghu/346/13
Wang et al. Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin
CN103146751A (zh) 新城疫病毒株rLX/H9HA及其构建方法和应用
WO2011024748A1 (ja) インフルエンザm2由来の改変ペプチドワクチン

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
ME Application for patent revocation filed
MEA Application cancelled (applic. for patent revocation filed)

Free format text: THE OWNER OF PATENT NO. 193196 HAS REQUESTED ITS CANCELLATION. THE REQUEST IS PUBLISHED FOR OPPOSITION BY INTERESTED PARTIES.